Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · July 03, 2014

Fourth Line Option for Stage 4 Patient Needed....

Heather Greene MSN, FNP, AOCNP

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Heather Greene MSN, FNP, AOCNP

Discuss This item

No comments yet, be the first to start the discussion!

  • Sylvia Richey MD

    Sylvia  Richey MD

    Jul 03, 2014

    Interesting case - and, all considered, the patient seems to be doing well. According to NCCN guidelines, treatment options after TKI failure include everolimus, axitinib, both category 1 recommendations, and sorafenib (category 2A) or bevacizumab or temserolimus (category 2B). Maybe axitinib?

  • adolfo salinas

    Aug 06, 2014

    Excellent Work

  • Satyanarayan Nandi

    Nov 16, 2014

    For a patient with somewhat similar case history, after right radical necherectomy,  suninib as a 1st line worked for 20 months, pazopnib as a 2nd line worked for 20 months. The patient has responded to axitinib on a 3rd line with a scan coming up.
  • Comment deleted by Moderator.

  • Nov 16, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated